An Open-label, Phase II Trial of Entospletinib (GS-9973), a Selective Spleen Tyrosine Kinase Inhibitor, in Diffuse Large B-cell Lymphoma
ConclusionEntospletinib monotherapy at 800 mg twice daily demonstrated limited activity in patients with advanced, relapsed DLBCL.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
More News: Anemia | Bilirubin | Cancer & Oncology | Chronic Kidney Disease | Chronic Leukemia | Constipation | Cough | Insomnia | Laboratory Medicine | Leukemia | Lymphoma | Myeloma | Study | Toxicology | Urology & Nephrology